TrialFrontiers in immunology2025

Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy.

Hongye Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.